BQNT 10001 is a small molecule (NCE) with potent inhibitory activity against carcinoma, leukemia and lymphoma cancers. Preclinical data suggests that BQNT 10001 is safe and orally bio-available. The company is in the process of finalizing the animal proof of concept studies.